Pharmacokinetics and metabolism of O-(chloroacetyl-carbamoyl) fumagillol (TNP-470, AGM-1470) in rhesus monkeys

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 2, 1996, Pages 117-122

  Cretton Scott, Erika ^a   Placidi, Laurent ^a   McClure, Harold ^b   Anderson, Daniel C ^b   Sommadossi, Jean Pierre ^a,c  

^a University of Alabama at Birmingham ^*  (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

angiogenesis; metabolism; monkeys; pharmacokinetics; TNP 470

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG METABOLITE; FUMAGILLOL CHLOROACETYLCARBAMATE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG METABOLISM; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOHEXANES; INJECTIONS, INTRAVENOUS; MACACA MULATTA; METABOLIC CLEARANCE RATE; SESQUITERPENES;

EID: 0029985206     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050458     Document Type: Article

References (20)

1. Adamson PC, Balis FM, Arndt CA, Holcenberg JS, Narang PK, Murphy RF, Gillespie AJ, Poplack DG (1991) Intrathecal 6-mercaptopurine: preclinical pharmacology, Phase I/II trial, and pharmacokinetic study. Cancer Res 51 : 6079
2. Berg SL, Balis FM, McCully CL, Godwin KS, Poplack DG (1993) Pharmacokinetics of PEG-L-asparaginase and plasma and cerebrospinal fluid L-asparagine concentrations in the Rhesus monkey. Cancer Chemother Pharmacol 32 : 310
3. Blaney SM, Cole DE, Balis FM, Godwin K, Poplack DG (1993) Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 53 : 725
4. Brem H, Folkman J (1993) Analysis of experimental antiangiogenic therapy. J Pediator Surg 28 : 445
5. Cretton EM, Schinazi RF, McClure HM, Anderson DC, Sommadossi JP (1991) Pharmacokinetics of 3′-azido-3′-deoxythymidine and its catabolites and interactions with probenecid in rhesus monkeys. Antimicrob Agents Chemother 35 : 801
6. Cretton EM, Zhou Z, Kidd LB, McClure HM, Kaul S, Hitchcock MJM, Sommadossi JP (1993) In vitro and in vivo disposition and metabolism of 3′-deoxy-2′,3′-didehydrothymidine. Antimicrob Agents Chemother 37 : 1816
7. DiPaolo JA, Tarbell DS, Moore GE (1958-1959) Studies on the carcinolytic activity of fumagillin and some of its derivative. Antibiot Annu 541
8. Figg W, Yeh H, Thibault A, Pluda J, Itoh F, Yarchoan R, Cooper M (1994) Assay of the antiangiogenic compound, TNP-470, and one of its metabolites, AGM 1883, by reverse-phase, high performance liquid chromatography in plasma. J Chromatogr 652 (2): 187
9. Gomeni R, Gomeni C (1978) Interactive graphic package for pharmacokinetic analysis. Comput Biomed Res 11 : 345
10. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Folkman J (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 348 : 555
11. Killough JH, Magill GB, Smith RC (1952) The treatment of amoebiasis with fumagillin. Science 115 : 71
12. Krishna DR, Klotz U (1994) Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 26 : 144
13. Kusaka M, Sudo K, Fujita T, Marui S, Itoh F, Ingber D, Folkman J (1991) Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Commun 174 : 1070
14. Marquardt DW (1963) An algorithm for least squares estimation of nonlinear parameters. J Soc Appl Math 11 : 431
15. Moore J, Sommadossi J-P and the AIDS Clinical Trial Group 215 Study Team (1995) Analysis of the angiogenic moderator o-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AMG-1470) and metabolites in plasma by high performance liquid chromatography-mass spectrometry. Mass Spectrum (in press).
16. Placidi L, Cretton-Scott E, DeSousa G, Rhamani R, Placidi M, Sommadossi J-P (1995) Disposition and metabolism of the angiogenic moderator O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470) in human hepatocytes and tissue microsomes. Cancer Res 55 : 3036
17. Pluda JM, Wyvill K, Figg WD, Whitcup SM, Lietzau J, Saville MN, Cohen R, Feigal E, Parks D, Foli A, Bailey J, Broder S, Yarchoan R (1994) A phase I study of an angiogenesis inhibitor, TNP-470 (AGM-1470), administered to patients (PTS) with HIV-associated Kaposi's sarcoma (KS). American Society of Clinical Oncology, Thirtieth Annual Meeting, Dallas, Tx.
18. Saville MW, Foli A, Broder S, Yarchoan R (1993) in vitro activity of TNP470, a novel angiogenesis inhibitor, in Kaposi's sarcoma (KS) related spindle cell lines. J Cell Biochem Suppl 17E : 22
19. Yanase T, Tamaru M, Fujita K, Kodama S, Tanaka K (1993) Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 53 : 2566
20. Zukiwski A, Gutterman J, Bui C, Sella A, Ellerhoust J, Tu S, Amato R, Figg W, Kilbourn R, Logothetis C (1994) Phase I trial of the angiogenesis inhibitor TNP-470 (AGM-1470) in patients (PTS) with androgen independent prostate cancer (Al Pea). American Society of Clinical Oncology, Thirtieth Annual Meeting, Dallas, Tx.